Clinical Trial

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.
Protocol Amendment History 1 change
minor Completion pushed: 2026-11 -> 2027-01 2026-07-08
Trial Details
NCT Number NCT04083599
Lead Sponsor Genmab
Collaborators: BioNTech SE
Conditions Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment 350 participants
Start Date 2019-09-17
Primary Completion 2025-12-30 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-04